Help - Search - Members - Calendar
Full Version: Crohns-Disease
Online Medical Forum > Library Database Of Journals Publications Researches Category > Library Database Of Journals Publications Researches > Medicine Category > Internal Medicine Forum > Medicine Topics > Crohns-Disease
Pages: 1, 2, 3, 4, 5, 6, 7
  1. Crohns: Anti tumour necrosis- therapy increases the number of foxp3+ regulatory t cells in children affected by crohns disease (0 replies)
  2. Crohns: Mucosal cytokine network in inflammatory bowel disease. (0 replies)
  3. Crohns: Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory. (0 replies)
  4. Crohns: Role of mucosal dendritic cells in inflammatory bowel disease. (0 replies)
  5. Crohns: New serological biomarkers of inflammatory bowel disease. (0 replies)
  6. Crohns: Esophageal crohn disease. (0 replies)
  7. Crohns: Crohn disease of the esophagus: a review of the literature. (0 replies)
  8. Crohns: Patient with severe crohn's disease became a father while on methotrexate and infliximab therapy (0 replies)
  9. Crohns: Researchers pinpoint genes linked to childhood inflammatory bowel disease (0 replies)
  10. Crohns: A new potential path to curing inflammatory bowel diseases emerges through gene research funded by the crohn's & colitis foundation of america (0 replies)
  11. Crohns: Role of muts homolog 2 (msh2) in intestinal myofibroblast proliferation during crohn's disease stricture formation (0 replies)
  12. Crohns: Fda urges more caution over tnf blocker infections (0 replies)
  13. Crohns: Early onset gene for inflammatory bowel diseases identified (0 replies)
  14. Crohns: The risk of developing crohn's disease after an appendectomy: a meta-analysis (0 replies)
  15. Crohns: Course of pediatric crohn's less complicated with early onset than with later onset (0 replies)
  16. Crohns: Early onset gene for inflammatory bowel diseases identified (0 replies)
  17. Crohns: Early onset gene for inflammatory bowel diseases identified (0 replies)
  18. Crohns: Discovery of novel candidate gene for inflammatory bowel diseases (0 replies)
  19. Crohns: Early onset gene for inflammatory bowel diseases identified (0 replies)
  20. Crohns: Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues (0 replies)
  21. Crohns: New genetic link to inflammatory bowel diseases discovered (0 replies)
  22. Crohns: Small intestinal cd103+ dendritic cells display unique functional properties that are conserved between mice and humans (0 replies)
  23. Crohns: Multislice ct compared to small bowel follow-through in the evaluation of patients with crohn disease. (0 replies)
  24. Crohns: Natalizumab (tysabri) for crohn's disease. (0 replies)
  25. Crohns: Hyperthermic stimulation of blood increases the immunological effects of granulocyte and monocyte adsorption in vitro: relevance to extracorporeal immunomodulation. (0 replies)
  26. Crohns: Association of the stat4 gene with increased susceptibility for some immune-mediated diseases (0 replies)
  27. Crohns: Expression of a splice variant of cxcr3 in crohn's disease patients; indication for a lymphocyte—epithelial cell interaction (0 replies)
  28. Crohns: Colonoscopy evaluation after short-term anti-tuberculosis treatment in nonspecific ulcers on the ileocecal area. (0 replies)
  29. Crohns: Oral crohn's disease: a favorable clinical response with delayed-release triamcinolone acetonide intralesional injections (0 replies)
  30. Crohns: Submucosal fat deposition in a patient with crohn's disease: the fat halo sign. (0 replies)
  31. Crohns: Biologic therapy for crohn's disease: clinical experience in patients who have had previous anti-tnf treatment (0 replies)
  32. Crohns: Grey-scale and colour doppler sonography in the evaluation of children with suspected bowel inflammation: correlation with colonoscopy and histological findings. (0 replies)
  33. Crohns: Deletion polymorphism upstream of irgm associated with altered irgm expression and crohn's disease (0 replies)
  34. Crohns: Azathioprine is effective for the treatment of both crohn's disease (cd) and ulcerative colitis. (0 replies)
  35. Crohns: Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in crohn's disease: a randomized multicenter trial (lir!c-trial) (0 replies)
  36. Crohns: Students with inflammatory bowel disease 'need more support' (0 replies)
  37. Crohns: Depression common in bowel disease patients (0 replies)
  38. Crohns: Octn and card15 gene polymorphism in chinese patients with inflammatory bowel disease. (0 replies)
  39. Crohns: [reviews] crohn's disease: current treatment options (0 replies)
  40. Crohns: [colorectal cancer] high frequency of early colorectal cancer in inflammatory bowel disease (0 replies)
  41. Crohns: [case reports] use of sirolimus (rapamycin) to treat refractory crohn's disease (0 replies)
  42. Crohns: [postscript] crohn's-like enterocolitis associated with mycophenolic acid treatment (0 replies)
  43. Crohns: [postscript] genetic variants in the autophagy pathway contribute to paediatric crohn's disease (0 replies)
  44. Crohns: Magi2 genetic variation and inflammatory bowel disease (0 replies)
  45. Crohns: Comprehensive disease control: can we differentiate among the biologic agents in crohn's disease? (slides with transcript) (0 replies)
  46. Crohns: Welcome and introduction: setting new treatment goals for crohn's disease in 2008 (slides with transcript) (0 replies)
  47. Crohns: Comprehensive disease control: can we differentiate among the biologic agents in crohn's disease? (slides with audio) (0 replies)
  48. Crohns: Welcome and introduction: setting new treatment goals for crohn's disease in 2008 (slides with audio) (0 replies)
  49. Crohns: Differentiating among biologic agents in crohn's disease: applying clinical data to daily treatment decisions (0 replies)
  50. Crohns: Managing crohn's disease in adults. (0 replies)
  51. Crohns: Multivesicular bodies in intestinal epithelial cells: responsible for mhc class ii-restricted antigen processing and origin of exosomes. (0 replies)
  52. Crohns: Hospitalised bowel patients at increased risk of blood clots (0 replies)
  53. Crohns: Methionine synthase a2756g polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase c677t pancolitis, in central china (0 replies)
  54. Crohns: Helicobacter species present in cd children's feces (0 replies)
  55. Crohns: Life begins at 40 for nhs occupational therapist who suffered from crohn's disease (0 replies)
  56. Crohns: Expanded adipose-derived stem cells for the treatment of complex perianal fistula including crohn's disease (0 replies)
  57. Crohns: [extended reports] the fcrl3 -169t>c polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a scandinavian panel of autoimmune diseases (0 replies)
  58. Crohns: Letters: fatty acid and vitamin d status in the epic trials of crohn disease treatment (0 replies)
  59. Crohns: Letters: fatty acid and vitamin d status in the epic trials of crohn disease treatment--reply (0 replies)
  60. Crohns: Pathogen that causes disease in cattle also associated with crohn's disease (0 replies)
  61. Crohns: Scheduled infliximab maintenance worthy for crohn's disease in uk (0 replies)
  62. Crohns: Scheduled infliximab maintenance worthy for crohn's disease in uk (0 replies)
  63. Crohns: Gene polymorphism tied to crohn's intestinal strictures (0 replies)
  64. Crohns: Scheduled infliximab maintenance worthy for crohn's disease in uk. (0 replies)
  65. Crohns: Scheduled infliximab maintenance worthy for crohn's disease in uk. (0 replies)
  66. Crohns: Adsorptive carbon product ameliorates anal fistulas in crohn's disease (0 replies)
  67. Crohns: Pathogen that causes disease in cattle also associated with crohn's disease - research urgently needed to evaluate potential risks to humans (0 replies)
  68. Crohns: Pathogen causing disease in cattle associated with crohn's disease (0 replies)
  69. Crohns: Rifaximin for the treatment of newly diagnosed crohn's disease: a case series (0 replies)
  70. Crohns: New podcast series from abbott for people living with crohn's disease (0 replies)
  71. Crohns: Asymptomatic ileal adenocarcinoma in the setting of undiagnosed crohn's disease. (0 replies)
  72. Crohns: Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. (0 replies)
  73. Crohns: Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in italy. (0 replies)
  74. Crohns: Inflammatory bowel disease: moving toward a stem cell-based therapy. (0 replies)
  75. Crohns: Pathogen that causes disease in cattle also associated with crohn's disease (0 replies)
  76. Crohns: Autoimmune disease in a dfna6/14/38 family carrying a novel missense mutation in wfs1 (0 replies)
  77. Crohns: Project: comparison of infliximab and ciclosporin in steroid resistant ulcerative colitis: a trial (construct) (0 replies)
  78. Crohns: Antibodies to flagellin indicate reactivity to bacterial antigens in ibs patients (0 replies)
  79. Crohns: Omega-3 fatty acids for maintenance of remission of crohn's disease. (0 replies)
  80. Crohns: The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis (0 replies)
  81. Crohns: A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for crohn's perianal fistulas (0 replies)
  82. Crohns: Basiliximab and infliximab for the treatment of steroid-refractory crohn's disease (0 replies)
  83. Crohns: Does it matter where you are hospitalized for inflammatory bowel disease? a nationwide analysis of hospital volume (0 replies)
  84. Crohns: Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients (0 replies)
  85. Crohns: Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease (0 replies)
  86. Crohns: Vertebral deformities common with inflammatory bowel disease (0 replies)
  87. Crohns: Meningitis in a patient with previously undiagnosed crohn's disease (0 replies)
  88. Crohns: Budesonide induction and maintenance therapy for crohn's disease during pregnancy (0 replies)
  89. Crohns: Biological therapy in crohn's disease: is it an issue of how hard you strike or how fast you strike? (0 replies)
  90. Crohns: Certolizumab pegol (0 replies)
  91. Crohns: Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. (0 replies)
  92. Crohns: Neuroimmunology of the gut: physiology, pathology, and pharmacology. (0 replies)
  93. Crohns: Hemophagocytic syndrome in an adolescent with crohn disease receiving azathioprine and infliximab. (0 replies)
  94. Crohns: Eosinophilic oesophagitis and other non-reflux inflammatory conditions of the oesophagus: diagnostic imaging and management. (0 replies)
  95. Crohns: [therapeutics] review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in crohn's disease (0 replies)
  96. Crohns: Infliximab for severe gastrointestinal bleeding in crohn's disease (0 replies)
  97. Crohns: Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations (0 replies)
  98. Crohns: Runt-related transcription factor 3 is associated with ulcerative colitis and shows epistasis with solute carrier family 22, members 4 and 5 (0 replies)
  99. Crohns: Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with crohn's disease: a randomized, double-blind, placebo-controlled pilot study (0 replies)
  100. Crohns: Atg16l1 t300a shows strong associations with disease subgroups in a large australian ibd population: further support for significant disease heterogeneity (0 replies)
  101. Crohns: A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active crohn's disease (0 replies)
  102. Crohns: Biologic therapy in crohn's disease: state of the art (0 replies)
  103. Crohns: Clinical significance of nod2/card15 and toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease. (0 replies)
  104. Crohns: Molecular basis of the potential of mesalazine to prevent colorectal cancer. (0 replies)
  105. Crohns: Mycophenolate mofetil promotes down-regulation of expanded b cells and production of tnf-alpha in an experimental murine model of colitis. (0 replies)
  106. Crohns: Monitoring 6-thioguanine nucleotide concentrations in japanese patients with inflammatory bowel disease (0 replies)
  107. Crohns: Ct enterography of crohn's disease. (0 replies)
  108. Crohns: Dapsone-responsive histiocytoid sweet's syndrome associated with crohn's disease. (0 replies)
  109. Crohns: Pill cam sb could help doctors treat children with crohn's (0 replies)
  110. Crohns: Scientists define 21 new genes associated with crohn's disease (0 replies)
  111. Crohns: Jama classics: crohn disease (0 replies)
  112. Crohns: 21 new genes found for crohn's disease (0 replies)
  113. Crohns: Scientists define 21 new genes associated with crohn's disease (0 replies)
  114. Crohns: Nutritional therapy for active crohn's disease. (0 replies)
  115. Crohns: Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. (0 replies)
  116. Crohns: Role of cytokines in inflammatory bowel disease. (0 replies)
  117. Crohns: Maintenance with infliximab effective in crohn's disease (0 replies)
  118. Crohns: Erythema nodosum associated with infliximab therapy. (0 replies)
  119. Crohns: Comparative analysis of bayer wide-range c-reactive protein (wr-crp) and the dade-behring high sensitivity c-reactive protein (hs-crp) in patients with inflammatory bowel disease (0 replies)
  120. Crohns: Neutrophil chemokines gcp-2 and gro-α in patients with inflammatory bowel disease (0 replies)
  121. Crohns: Specific 5q31 variants linked to psoriasis risk (0 replies)
  122. Crohns: Notched sign and bamboo-joint-like appearance in duodenal crohn's disease (0 replies)
  123. Crohns: Case points to link between crohn's treatment, cancer (0 replies)
  124. Crohns: Case points to link between crohn's treatment, cancer (0 replies)
  125. Crohns: Case points to link between crohn's treatment, cancer (0 replies)
  126. Crohns: Role of muts homologue 2 (msh2) in intestinal myofibroblast proliferation during crohn's disease stricture formation. (0 replies)
  127. Crohns: Stem cells heal chronic inflammation in the gut - may help restore immune system to normal function for crohn's disease (0 replies)
  128. Crohns: Spotlight on infliximab in crohn disease and rheumatoid arthritis (0 replies)
  129. Crohns: Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in crohn's disease (0 replies)
  130. Crohns: Spinal deformities common in bowel disease patients (0 replies)
  131. Crohns: Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease (0 replies)
  132. Crohns: [postscript] nitazoxanide for cryptosporidial infection in crohn's disease (0 replies)
  133. Crohns: Extended immunosuppression 'no advantage' in crohn's disease (0 replies)
  134. Crohns: Conquering crohn's disease: where to next? (0 replies)
  135. Crohns: Paraoxonase-1 status in crohn's disease and ulcerative colitis (0 replies)
  136. Crohns: Il-23r determines susceptibility in crohn's disease in a mediterranean area (0 replies)
  137. Crohns: Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in crohn's disease (0 replies)
  138. Crohns: Adjustment to inflammatory bowel disease: the relative influence of illness perceptions and coping (0 replies)
  139. Crohns: Glatiramer acetate: a novel therapeutic approach in crohn's disease? (0 replies)
  140. Crohns: Expanding role of capsule endoscopy in inflammatory bowel disease. (0 replies)
  141. Crohns: Use of the crohn's disease activity index in clinical trials of biological agents. (0 replies)
  142. Crohns: Conquering crohn's disease: where to next? (0 replies)
  143. Crohns: Anti-adhesion molecule strategies for crohn disease. (0 replies)
  144. Crohns: The v249i polymorphism of the cx3cr1 gene is associated with fibrostenotic disease behavior in patients with crohn's disease. (0 replies)
  145. Crohns: Anti-adhesion molecule strategies for crohn disease (0 replies)
  146. Crohns: Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease (0 replies)
  147. Crohns: [extended reports] focus on adverse events of tumour necrosis factor {alpha} blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients (0 replies)
  148. Crohns: Intestinal barrier dysfunction in inflammatory bowel diseases (0 replies)
  149. Crohns: Long-term health outcomes in pediatric inflammatory bowel disease: a population-based study (0 replies)
  150. Crohns: Prevalence of penetrating disease and extraintestinal manifestations of crohn's disease detected with ct enterography (0 replies)
This is a "lo-fi" version of our main content. To view the full version with more information, formatting and images, please click here.
Invision Power Board © 2001-2008 Invision Power Services, Inc.